ATAI:NASDAQ
AtaiBeckley Inc
$7.26
arrow_upward
+0.14%(+0.010) 1D
Aug 14, 4:00:01 PM GMT-4 · USD
search
All symbols
1D
5D
1M
6M
YTD
1Y
5Y
MAX
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for ATAI...
Open
$7.24
High
$7.28
Low
$7.23
Mkt. cap
2.69B
Avg. vol.
16.13M
Volume
0.00
52-wk high
$7.28
52-wk low
$3.26
EPS
-$2.18
Beta
1.55
Shares outstanding
370.86M
No. of employees
99
Open
$7.24
High
$7.28
Low
$7.23
Mkt. cap
2.69B
Avg. vol.
16.13M
Volume
0.00
52-wk high
$7.28
52-wk low
$3.26
EPS
-$2.18
Beta
1.55
Shares outstanding
370.86M
No. of employees
99
News stories
From web sources and news partners
Profile
AtaiBeckley Inc. is a clinical-stage biotechnology company developing treatments for mental health disorders, including therapies based on psychedelics, entactogens, and related compounds. The company was founded in November 2025 through the combination of atai Life Sciences N.V. and Beckley Psytech Limited. atai Life Sciences was founded in 2018 and became a publicly listed company in 2021. Beckley Psytech, a private company, was founded in 2019. In December 2025, the combined company redomiciled from the Netherlands to the U.S., incorporated in Delaware and headquartered in New York, NY. The company's shares trade on the Nasdaq stock exchange under the ticker symbol ATAI.
The company's pharmaceutical candidates include mebufotenin for treatment-resistant depression, dimethyltryptamine for treatment-resistant depression, and-midomafetamine for social anxiety disorder. The company is also advancing a drug discovery program to identify novel, non-hallucinogenic 5-HT2AR agonists for opioid use disorder and treatment-resistant depression. Wikipedia
About AtaiBeckley Inc
CEOFlorian Brand
Employees99
Founded2018
Headquarters-
SectorPharmaceutical industry
Websiteataibeckley.com
AI content may include mistakes. Learn more